LYG-202 is a novel piperazine-substituted flavonoid exhibiting antitumor activity. It induces apoptosis and elevates reactive oxygen species (ROS) in breast cancer cell lines such as MCF-7, MDA-MB-231, and MDA-MB-435, demonstrating potential for oncology research in both cellular and animal models.